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ABSTRACT
Background: Volanesorsen, an investigational inhibitor of apoC-III synthesis, significantly reduced
triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome (FCS), a rare
genetic disorder characterized by marked chylomicronemia leading to a spectrum of symptoms,
including recurrent abdominal pain and episodes of potentially fatal acute pancreatitis (AP).
Objective: To determine the effect of volanesorsen on burden of disease on patients with FCS
Methods: ReFOCUS was a retrospective global web-based survey open to patients with FCS who
received volanesorsen for ≥3 months in an open-label extension study. The survey included questions
about patients’ experiences before and after volanesorsen treatment.
Results: Twenty-two respondents had received volanesorsen for a median of 222 days. Volanesorsen
significantly reduced the number of symptoms per patient across physical, emotional, and cognitive
domains. Significant reductions from baseline were reported for steatorrhea, pancreatic pain, and
constant worry about an attack of pain/AP. Respondents reported that volanesorsen improved overall
management of symptoms and reduced interference of FCS with work/school responsibilities.
Reductions in the negative impact of FCS on personal, social, and professional life were also reported.
Conclusions: Treatment with volanesorsen has the potential to reduce disease burden in patients with
FCS through modulation of multiple symptom domains.
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1. Introduction
Familial chylomicronemia syndrome (FCS) is a rare metabolic
disorder characterized by reduced or absent lipoprotein lipase
(LPL) activity [1,2]. LPL catalyzes the hydrolysis of triglycerides
(TG) in chylomicrons and other TG-rich lipoproteins, and its
absence or functional impairment leads to marked fasting and
postprandial chylomicronemia and plasma TG levels that are
10–100-fold above the normal value (150 mg/dL, 1.7 mmol/L)
[3]. Because of chylomicron accumulation, many patients with
FCS experience a variety of symptoms and signs including
frequent abdominal pain, eruptive xanthomas, lipemia retina-
lis, and hepatosplenomegaly. Acute pancreatitis (AP) presents
the most significant risk in patients with FCS, which is asso-
ciated with major morbidity and even mortality [4]. Potential
long-term complications as a result of AP include chronic
pancreatitis, that may manifest as endocrine pancreatogenic
(type 3c) diabetes and endocrine and exocrine pancreatic
insufficiencies [5]. It is documented that AP due to severely
high TG may be more severe with worse outcomes than
pancreatitis from other etiologies [6]. High TG levels are inde-
pendently and proportionally correlated with persistent organ
failure in AP, with 48% rate of organ failure observed in AP
patients with TG levels >1000 mg/dL compared with 30% and
39% in AP patients with TG levels of 150–199 mg/dL and
200–999 mg/dL, respectively; 45% of patients with HTG (TG
≥200 mg/dL) required ICU care compared with 23% of
patients with normal TG (<150 mg/dL) [7]. A population-
based study has calculated that every 100 mg/dL increase in
TG concentration increased the risk of AP by 4% [8]. Although
mortality associated with AP in FCS patients is not known,
mortality from HTG-associated AP has been estimated at
5–6%, and as many as 30% of patients with severe complica-
tions (pancreatic necrosis in association with infected
abscesses or persistent multiple organ failure) may die [1,2].
Pregnancy in the absence of FCS causes a 2–3-fold increase in
TG levels because of the associated rise in endogenous estro-
gens, and thus poses a particular problem for women with FCS
[9–11].
There are no currently available approved treatments for
FCS, and long-term management relies mainly on adherence
to an extremely restrictive, low-fat diet (10–20 g daily) and life-
long avoidance of alcohol and medications known to increase
TG levels, such as glucocorticoids, atypical antipsychotic drugs,
protease inhibitors, antiretroviral agents, retinoids, thiazides,
beta-blockers, and exogenous estrogen [2,12]. Lifetime com-
pliance with such an extremely restrictive diet is difficult, may
negatively impact quality of life, does not normalize TG levels
in all patients, and therefore does not completely obviate the
risk of pancreatitis or other symptoms in all patients [1,13].
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Lipid-lowering agents such as fibrates, omega-3 fatty acids,
and niacin are largely ineffective in FCS, primarily because
they act by decreasing hepatic VLDL output and by enhancing
LPL activity but ultimately require a functional LPL pathway,
which is severely impaired or absent in FCS patients [1,2].
A recently discovered method to lower TG levels in patients
with FCS is to target plasma apoC-III, a small, 79-amino-acid glyco-
protein that raises plasma TG levels through potent inhibition of
LPL activity and also through a non-LPL-dependent mechanism
[14–16]. Volanesorsen sodium, an investigational drug being
developed for the reduction of TGs in patients with FCS, is a
second-generation antisense inhibitor of apoC-III synthesis, which
binds to hepatic APOC3 mRNA and elicits the degradation of
mRNA by the endogenous ribonuclease RNase H1 [16]. The
APPROACH trial was a randomized, double-blind, placebo-con-
trolled phase III study (ISIS 304801-CS6; APPROACH: A
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of
ISIS 304801 Administered Subcutaneously to 66 Patients With
Familial Chylomicronemia Syndrome (FCS); NCT02211209) con-
ducted to evaluate the efficacy and safety of volanesorsen
(300 mg subcutaneously once a week) compared with placebo in
patients over the age of 18 years with FCS. In this study, currently
the largest in this population, the primary end point at 3 months
was met with a 94% decrease in TG in the volanesorsen-treated
group compared to the placebo group (P < 0.001). Treatment with
volanesorsen reduced TG levels by 77% when compared to base-
line at 3 months, as opposed to an 18% increase with placebo
(P < 0.001). The incidence of AP events was also reduced during
treatment, with 1 AP event in a volanesorsen-treated patient
compared with 4 events in 3 placebo-treated patients. However,
the low frequency of recorded AP events over the 52-week dura-
tion of the study limited statistical comparison. Themost common
adverse events with volanesorsen were injection site reactions
(17% of all injections). Declines in platelet counts led to 5 early
terminations in APPROACH, 2 of which had platelets <25,000/µl;
platelet counts recovered to normal following treatment with
corticosteroids and cessation of volanesorsen [17].
Patient-reported outcomes, including health-related quality
of life (QoL), are key considerations for understanding the
burden and impairment associated with a chronic disease,
and for assessing the effectiveness of treatment. Although
the physical symptoms and other clinical features of FCS are
well defined in the existing literature, the effects of FCS on
patients’ QoL, including emotional, cognitive, and psychoso-
cial well-being were, until recently, poorly understood. To
address this gap in the literature on QoL of patients with
FCS, a multinational web-based survey, Investigation of
Findings and Observations Captured in Burden of Illness
Survey in FCS Patients (IN-FOCUS), was conducted to assess
the QoL and multidimensional burden in patients with FCS;
the survey design and interim analysis have been published
[4]. An interim analysis of 60 patients in this study highlighted
the multiple and heterogeneous symptoms experienced by
these patients [4]. Between 22% and 35% of patients experi-
enced severe physical symptoms such as bloating, abdominal
pain, asthenia, fatigue, indigestion, and pancreatic pain; 42%
reported an history of AP. The constant threat of debilitating
or potentially fatal AP severely impacted the well-being of one
third of patients. Patients with FCS generally reported
themselves to be underemployed and more than 90% of
respondents in the IN-FOCUS study indicated that FCS had
negatively influenced their employment opportunities and
career choices. FCS had directly caused 68% of full- or part-
time employed patients to take time off from work, reporting
missing a mean of 30 days of work in a year because of their
FCS symptoms. Additionally, 81% and 70% of patients in the
global IN-FOCUS study reported that applying the dietary
restriction was extremely time consuming and energy drain-
ing, respectively, and the constant planning and management
of their diet was a source of anxiety and social withdrawal.
Further, 53% of patients continued to experience symptoms
despite compliance to their extremely restricted low-fat diet
and lifestyle prescriptions [18].
Upon completion of the APPROACH study, eligible patients
could elect to receive volanesorsen in an open-label extension
(OLE) study. Since the IN-FOCUS study revealed the extensive
burden of disease and the poor QoL experienced by patients
with FCS, it is important to determine whether the reduction
of TGs with volanesorsen in APPROACH translates into
improved QoL for these patients or a mitigation of the myriad
burdens identified in IN-FOCUS. The Retrospective Findings
and Observations Captured in Burden of Illness Survey in FCS
Patients (ReFOCUS) study was conducted to evaluate burden
of illness and QoL of patients with FCS before and during
treatment with volanesorsen. A questionnaire, adapted from
the IN-FOCUS questionnaire, was applied to an eligible popu-
lation from the APPROACH OLE study to determine whether
treatment with volanesorsen also reduced the clinical and
psychosocial burdens that impact patients’ QoL and interfered
with their personal, social, and professional well-being.
2. Methods
2.1. Study design
ReFOCUS was a global online, quantitative research study that
consisted of a web-based survey designed to retrospectively
record the burden of living with FCS in patients before and
after treatment with volanesorsen in the APPROACH OLE study
(NCT02658175). The survey was open to patients in the USA,
Canada, the UK, South Africa, Spain, France, Netherlands,
Germany, Italy, Brazil, and Israel and was available in multiple
languages in addition to English. Respondents had the option
to complete the survey over multiple sessions.
All current or former participants in the APPROACH OLE
study of volanesorsen for the treatment of FCS were invited to
participate in the survey. To be considered for participation in
the ReFOCUS study, patients must have been enrolled in the
APPROACH OLE and have received one or more injections of
volanesorsen. All eligible patients at the time of study recruit-
ment (N = 58) were invited to participate in the survey by the
OLE Principal Investigators, who directed potential respon-
dents to the study website. All patients were requested to
complete the ‘pre-volanesorsen’ portion of the questionnaire;
no response was received from patients who chose not to
participate (n = 23) despite multiple follow ups. Only patients
who received treatment with volanesorsen for ≥3 months in
APPROACH OLE completed sections pertaining to their
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experience during the most recent 3-month period while on
the treatment. ‘Before and after’ data were available for 22
respondents. Patients continued all other management strate-
gies per APPROACH OLE protocol (i.e. maintained a fat-restric-
tive diet, take TG-lowering medication, and alcohol
avoidance). The research and study team were blinded to
the identity of survey respondents. Respondents who com-
pleted the full survey were offered a nominal honorarium to
compensate for time spent completing the survey.
All research materials were approved by the Institutional
Review Board of the University of Mississippi in the USA and
the National Health Service South West – Frenchay Research
Ethics Committee in the UK. Ethics Committee approval was
sought and received for centers based outside the USA and
UK, as required.
2.2. Questionnaire
The questionnaire used in ReFOCUS was adapted from the IN-
FOCUS questionnaire, a prior burden of illness study conducted
in patients with FCS [4]. The questionnaire consisted of sections
on screening criteria and demographics; diagnosis; symptoms;
FCS management; impact of FCS on personal, social, and profes-
sional life, mental and physical health, and diet; and comorbid-
ities and lifetime events. ReFOCUS was designed as a classic, pre-
vs. post-study, to retrospectively capture the daily burden of
living with FCS across two different time-periods, the 3 months
prior to receiving volanesorsen and the most recent 3 months
since on volanesorsen. The draft questionnaire was tested
through a direct interview with two eligible respondents from
the USA to ensure comprehensiveness and relevance to respon-
dents’ condition and situation, before the survey was launched.
The survey website (www.FCSReFOCUS.com) was active
between 12 July 2017 and 3 November 2017. Toluna USA Inc.,
a third-party programming and data hosting company, hosted
the website and housed data generated by the study.
2.3. Statistical analysis
Data are shown for 22 respondents who completed the ques-
tionnaire for both ‘before’ and ‘after’ time periods. Continuous
variables were presented as mean with standard deviation, or
median with ranges. Categorical variables were presented as
frequencies and percentage of occurrence of each category.
Rating scales additionally were presented as medians with inter-
quartile ranges (Q1–Q3) and percent changes in mean rank from
baseline were calculated using geometric means. Wilcoxon
Signed Rank tests were conducted to test for differences in
mean ranks before and after taking volanesorsen. This test was
used over a t-test to account for the ordinal nature of these data.
Data analysis was performed using SPSS Statistics 22 (Armonk,
NY). P < 0.05 was considered to be statistically significant.
3. Results
3.1. Respondent characteristics
A total of 58 eligible patients from the APPROACH OLE (41 of
whom had been on volanesorsen for at least 3 months) were
invited to participate in the study. Exclusions are explained in
the flowchart in Supplementary Figure 1; these include 23
patients who did not visit the website, 7 patients who did
not complete screening and 3 additional patients who did not
complete the survey. Of a final study sample of 25 respon-
dents, 22 had been treated with volanesorsen for at least
3 months; 3 were excluded as they were treated with volane-
sorsen for <3 months (Supplementary Figure 1). Baseline char-
acteristics are shown in Table 1. A majority of respondents
were female (73%) and 55% were from North America (the
USA and Canada). The median age at the time of the survey
was 51 years (range, 26–65 years), with a majority of respon-
ders (68%) between 41 and 60 years. The median age at
diagnosis was 24 years (range, 0–63 years); 9 respondents
(41%) were diagnosed with FCS before the age of 10 years.
Of 11 patients who could recall their TG levels at diagnosis, 10
had TG levels ≥1500 mg/dL. The median duration on volane-
sorsen therapy was 222 days (~7.5 months); 68% had been
treated for >6 months when they completed the survey.
Following observation for platelet decline, the protocol was
amended to include alternative dosing schedule including
biweekly dosing and 64% of respondents were taking volane-
sorsen on a biweekly basis.
Survey respondents (19 who could recall their path to
diagnosis) had been seen by an average of 3 physicians
(range, 1–15) before being diagnosed with FCS; however, 5
patients (23%) had visited 4–6 physicians and 1 had visited
13–15 physicians before diagnosis. Most commonly, the diag-
nosis of FCS was made by a metabolic specialist (N = 5; 23%)
or lipidologist (N = 4; 18%). Misdiagnoses were common; 12
(55%) respondents reported a misdiagnosis, most commonly
hypertriglyceridemia (N = 6; 50%), other (N = 5; 42%), or AP of
unknown cause (N = 4; 33%) before being diagnosed correctly
with FCS. Misdiagnoses were most commonly made by a
primary care physician (N = 5, 42%), ER doctor/intensivist
(N = 4, 33%), pediatrician (N = 4, 33%), or gastroenterologist
(N = 2, 25%).
3.2. Management of FCS
A 7-point Likert scale (1 = ‘strongly disagree;’ 7 = ‘strongly
agree’) was used to assess patients’ perceptions of and experi-
ence with managing the symptoms of FCS before starting
volanesorsen and after at least 3 months of treatment.
Respondents indicated that they believed their FCS was
being more effectively managed when treated with volane-
sorsen compared with their previous management regimen
(Figure 1). Notably, after volanesorsen treatment, more
respondents reported that their strategies for managing the
symptoms of FCS were effective (40% vs. 19%) and that their
symptoms were controlled with adherence to diet (90% vs.
55%). Managing symptoms during the 3-month treatment
period was also reported to be significantly less time consum-
ing and energy draining, compared with the pretreatment
period. Despite noting the greater efficacy and ease of dietary
management while on volanesorsen treatment, patients con-
tinued to be highly focused and obsessive/rigid about adher-
ing to their diet during treatment.
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3.3. Symptomology
Respondents were asked to indicate symptoms they experi-
enced during pre- and post-volanesorsen treatment periods
from a list of 41 symptoms categorized into three domains:
physical, emotional, and cognitive. Overall, the median num-
ber of symptoms experienced after initiating volanesorsen
treatment decreased from 6.5 (Q1–Q3 = 2.0–13.0) prior to
volanesorsen treatment to 3.5 (Q1–Q3 = 1.5–6.5) after at least
3 months of treatment (34% improvement; P < 0.05). Likewise,
the number of respondents who experienced greater than 10
symptoms decreased from 41% prior to volanesorsen treat-
ment to 14% after treatment (improvement from baseline,
66%) (Figure 2). Treatment significantly reduced the number
of symptoms experienced per patient in all three domains,
with decreases from baseline of 47% (2.4 vs. 4.5; P = 0.009),
47% (1.9 vs. 3.5; P = 0.007), and 46% (0.3 vs. 0.6; P = 0.030) in
physical, emotional, and cognitive domains, respectively.
Among physical symptoms, a significant reduction in inci-
dence was reported for pancreatic pain (from 8 respondents
to 1, P < 0.05), steatorrhea (from 5 respondents to 0, P < 0.05),
physical weakness/asthenia (from 6 respondents to 2,
P < 0.05), fatigue (from 10 respondents to 4, P < 0.05) and
back pain (from 8 respondents to 4, P < 0.05) (Figure 3A). All
but four physical symptoms were reported by fewer respon-
dents following ≥3 months of volanesorsen treatment; skin
rash, chills, lack of appetite, and headaches remained
unchanged. Among emotional symptoms, the constant worry
about having an attack of pain or AP at any time was reduced
from 10 respondents to 2 (P < 0.05), and similar significant
reduction in incidence was reported for feeling out of control
because of FCS (from 5 respondents to 1, P < 0.05) and anger/
frustration with having FCS (from 7 respondents to 3, P < 0.05)
(Figure 3B). All emotional symptoms, other than social with-
drawal/feeling isolated also showed reduced incidence. In
general, <20% of patients experienced cognitive symptoms
at baseline (Figure 3C); the numbers of patients experiencing
these declined or remained steady after 3 months of treat-
ment. Notably, no respondent reported an increase in the
number of symptoms experienced while taking volanesorsen.
For many of the symptoms, the sample size was too small to
analyze. However, the reported average severity was lower for
indigestion (27%), generalized, diffuse, non-localized abdom-
inal pain (18%), bloating (17%), skin changes (20%), and
xanthoma (18%). Emotional symptoms whose average severity
was lowered following volanesorsen treatment were feeling
misunderstood/not understood (42%), embarrassment over
constantly thinking about/planning for food (30%), anger/
fear/worry in social situations because of food (22%).
In the 3 months before starting volanesorsen, 10 respondents
(45%) experienced general abdominal pain or pancreatic pain.
Abdominal pain was defined as ‘generalized abdominal pain,
diffuse and non-localized’ while pancreatic pain was defined as
‘deep-seated pain that is most often felt in the back, makes it
hard to get comfortable.’ Of those, 2 patients (20%) required
hospitalization. After at least 3 months of treatment with vola-
nesorsen, only 4 respondents (18%) reported these symptoms,
reflecting a 60% decrease. Of these 4 respondents, none required
hospitalization during treatment. Following treatment with
Table 1. Baseline demographics and characteristics.
Patient characteristics
Patients
N = 22
Female gender, n (%) 16 (73)
Age at time of survey, median (range), years 51 [26–65]
Age at FCS diagnosis, years, median (range) 24 [0–63]
≤10 9 (41)
11–20 1 (5)
21–30 5 (23)
31–40 2 (9)
41–50 1 (5)
51–60 3 (14)
≥61 1 (5)
Country of residence, n (%)
USA 7 (32)
Canada 5 (23)
Italy 4 (18)
UK 3 (14)
Spain 2 (9)
South Africa 1 (5)
Family history of FCS, n (%) 15 (68)
No. of physicians seen before diagnosis, median [range] 3 [1–15] *
1–3 13 (59)
4–6 5 (23)
7–9 0 (0)
10–12 0 (0)
13–15 1 (5)
Unable to recall 3 (14)
Patients with misdiagnoses, n (%)
No 8 (36)
Yes 12 (55)
Unable to recall 2 (9)
Data are shown as n (%), unless indicated otherwise
* Data from N = 19 who were able to recall this information; N = 3 selected ‘I don’t know’.
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Figure 1. Approaches used to manage symptoms of FCS.
N = 20 unless otherwise stated. *P < 0.05 vs. baseline. aN for PRE = 21; bN = 16; cN for PRE = 16; dImprovement defined as decrease in mean rank rating in past 3 months versus 3 months prior to
starting treatment with volanesorsen; exception: ‘My approach to managing. . .,’ where improvement is defined as an increase in mean rank rating. Medians for the ratings scales pre- and post-
treatment are shown with the interquartile ranges (Q1–Q3).
Figure 2. Number of symptoms of FCS experienced before and after being treated with volanesorsen.
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(a)
(b)
(c)
Figure 3. (A)(B)(C). Effect of volanesorsen treatment on (A) physical symptoms, (B) emotional symptoms, and (C) cognitive symptoms.
Numbers in parentheses indicate the number of patients in the pretreatment period who experienced each symptom. *P < 0.05
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volanesorsen, the incidence of AP decreased by 80% from 5
patients (4 had experienced 1–2 episodes and 1 with >5 epi-
sodes) pretreatment to 1 patient (experiencing between 1 and 2
episodes while on treatment). Because of the small sample size,
improvement in the average severity of pancreatic pain could
not be determined.
3.4. Impact of disease on personal, social, and
professional life
The impact of FCS on the respondents’ personal, social, and
professional life was assessed on a 7-point Likert scale (1 = ‘no
interference at all;’ 7 = ‘significant interference’). When consider-
ing the overall impact of FCS on their lives, the proportion of
respondents who reported ‘no interference’ increased from 5%
prior to volanesorsen to 23% while on therapy, whereas those
reporting a high level of interference (rating of 5–7) decreased
from 59% prior to treatment to 37% while on volanesorsen
(Figure 4). Symptoms of FCS had a significantly lower impact
on respondents’ lives during volanesorsen treatment, with a 31%
reduction in mean score from baseline (median 5.0 (Q1–Q3 = 2.0–
6.0) versus 2.5 (Q1–Q3 = 2.0–5.0); P < 0.05). The ability to fulfill
their responsibilities at work or school while being treated with
volanesorsen improved; the score for overall FCS-related inter-
ference with work/school decreased 39% compared with before
starting volanesorsen (median: 2.0 (Q1–Q3 = 1.0–5.0) versus 1.0
(Q1–Q3 = 1.0–2.0); P < 0.05). The proportion of respondents who
reported no interference of FCS with work or school increased
from 36% before starting volanesorsen to 64% during treatment
(Figure 5).
Participation in household and personal activities improved
during volanesorsen treatment, with a lower proportion of
respondents reporting a high level of interference (rating
5–7) of FCS with eating out (23% vs. 59%), taking vacations
(14% vs. 38%), pursuing hobbies (5% vs. 23%) and taking care
of others (0% vs. 10%) (Supplementary Figure 2). Treatment
with volanesorsen improved their reported ability to partici-
pate in social activities, such as entertaining and traveling, and
the ability to socialize and engage with others (Supplementary
Figure 3). Respondents reported reduced stress over mana-
ging diet and difficulty over food planning while on volane-
sorsen treatment. Several aspects of emotional and mental
well-being, including stress and anxiety, feelings of self-
worth, and sleep quality also improved significantly after treat-
ment with volanesorsen (Supplementary Figure 4).
Importantly, there was a shift in attitude about the future; at
Figure 4. Overall impact of FCS on patients’ lives before and after volanesorsen treatment (N = 22).
Figure 5. Interference of FCS with work/school attendance and responsibilities before and after treatment with volanesorsen (N = 22).
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baseline, 67% of respondents were worried about ever being
able to lead a normal life, compared with 36% who expressed
this concern after volanesorsen treatment (Supplementary
Figure 5).
When time to feeling better was examined, 14% and 43%
of respondents felt markedly better within a month and
between 1 and 2 months, respectively, and 25% and 56%
felt somewhat better within a month and between 1 and
2 months, respectively (Supplementary Figure 6). Overall, the
median time to feeling ‘somewhat better’ was 42 days and for
‘markedly better,’ 60 days.
4. Discussion
Patients with FCS describe frequent chronic, debilitating
abdominal pain and less frequent but significant and poten-
tially life-threatening bouts of AP, despite following a strict,
extremely restrictive low-fat diet. In addition to the burden of
physical symptoms, patients with FCS describe significant
cognitive, psychosocial, emotional, and economic burden.
Specifically, their testimonies reference the impact of FCS
symptoms on QoL (i.e. fatigue, mental fog, anxiety/fear
about next attack) and job performance (missed days due to
sickness or hospitalization). The phase III APPROACH study
demonstrated that treatment with volanesorsen significantly
reduced TG levels by 94% in patients with FCS when com-
pared to placebo at the primary end point [17]. While receiv-
ing treatment with volanesorsen, respondents in the ReFOCUS
study described an overall improvement in their health and
QoL, reporting a significant decrease in the total number of
FCS-related symptoms, across all domains assessed.
Respondents reported more effective overall FCS manage-
ment during treatment with volanesorsen. Patients with FCS
generally adhere to a strict very low-fat diet. The IN-FOCUS
study has chronicled the stress and anxiety and the interference
with all spheres of life attendant to following such a restricted
diet to control symptoms [4]. Before starting volanesorsen
treatment, many respondents noted that, despite adhering to
their diet, they still experienced symptoms and that their
approach to managing symptoms was time consuming, energy
draining, and not completely effective. The addition of volane-
sorsen to dietary management resulted in better symptom
control and, overall, respondents felt that their FCS manage-
ment strategies became more effective, and dietary manage-
ment easier. Regardless, most patients reported continued
adherence to their diet when on volanesorsen treatment.
The symptoms experienced by the respondents in
ReFOCUS before initiating treatment with volanesorsen were
broadly similar to those captured in the IN-FOCUS study and
were poorly controlled despite adherence to a highly restric-
tive very low-fat diet. Notably, patients treated with volane-
sorsen reported a significant decrease in the total number of
FCS-related symptoms experienced. The proportion of
patients experiencing steatorrhea and pancreatic pain
declined significantly. The incidence of AP and hospitalization
due to generalized abdominal pain/pancreatic pain also
decreased following volanesorsen treatment. The reduction
in physical symptoms, especially attacks of pain or AP, was
accompanied by an improvement in respondents’ emotional
outlook; in particular, the constant uncertainty of having an
attack of pain or AP was significantly reduced (P < 0.05).
Although only a few respondents reported cognitive decre-
ments at baseline, volanesorsen treatment reduced brain fog
and symptoms such as forgetfulness and recent memory loss.
It is notable that these improvements occurred even though
two-thirds of the patients on the alternative dosing schedule
took volanesorsen every 2 weeks.
Beyond the direct improvement on FCS symptomology,
volanesorsen treatment had a broader impact on patients’
ability to fulfill their responsibility at work or school, and to
perform and participate in household and personal activities,
all of which were improved with volanesorsen. The baseline
data from this study and data from IN-FOCUS [4,18] both
highlighted the negative influence of FCS on careers, employ-
ment opportunities, and work productivity. Treatment with
volanesorsen decreased the reported overall interference of
FCS with work or school (the proportion of respondents
reporting no interference of FCS with work/school increased
by 77%), suggesting that improved disease management with
volanesorsen treatment may increase productivity and reduce
absenteeism. Likewise, reduced symptom prevalence may
translate into broadly reduced healthcare resource utiliza-
tion [19].
The reduction in the assessed variables and burdens also
translated to functional and social outcomes. For example,
improvement was noted in patients’ reported ability to go
out to restaurants, take family vacations, actively engage in
various hobbies, and entertain and socialize. Perhaps the most
impactful finding from the ReFOCUS survey was the improve-
ment in respondents’ mental wellbeing and future outlook on
their life and health compared to before they started on
volanesorsen treatment.
While the available literature discusses the physical, emo-
tional, and cognitive manifestations associated with FCS,
there is little, if any evidence on the impact of pharmacother-
apy on the QoL in patients with FCS. The phase III APPROACH
study showed that volanesorsen significantly reduced TG
levels in patients with FCS. Following 3 months of treatment
with volanesorsen, mean TG decreased 77% from baseline,
compared with an increase of 18% with placebo; 77% and
50% of volanesorsen-treated patients had TG reductions to
<750 mg/dL and 500 mg/dL, respectively [17]. These are
levels generally below the threshold for AP [20]. TG levels
were not measured in the ReFOCUS study, but together with
the data from APPROACH, the ReFOCUS findings suggest that
the lower TG levels following volanesorsen treatment may be
associated with the reduction in AP and abdominal pain and
a generally improved symptom profile reported by the
respondents. The present survey demonstrated that treat-
ment with volanesorsen improved the physical, emotional
and cognitive domains associated with FCS. These improve-
ments led to a significantly improved overall ability to per-
form professional, academic, and social obligations. The
research highlights considerable improvement across
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multiple domains achieved in this patient population with
volanesorsen treatment and provides encouraging data that
underscores the need for a therapeutic option such as
volanesorsen.
The study has several limitations, which should be considered
when assessing the significance of the study findings. In particular,
when enrolling patients with a rare disease in clinical studies, there
are inherent restrictions on potential sample size, study design,
and respondent recruitment options. In this case, the sample size
was limited to 22 self-selected respondents enrolled in the
APPROACH OLE study, representing only 6 of the 12 countries
that participated in the APPROACH study. Second, as the survey
findings were self-reported, it was not possible to independently
verify the experiences reported by patients. Since all the patients
were recruited from the OLE, there was no comparator group to
distinguish the differences seen in patients receiving volanesorsen
treatment versus patients without treatment. Finally, with a retro-
spective pre-/posttreatment study design the potential influence
of recall bias in patient reported outcomes, particularly the risk of
overstating the efficacy in the context of a new treatment option
being offered for an underserved population and/or misremem-
bering their symptoms, must also be considered. To mitigate this
effect in the ReFOCUS study, survey responses were gathered
several months following volanesorsen initiation (median time
on therapy of 222 days) and from respondents from both arms
of the randomized, placebo-controlled APPROACH study who
entered the OLE study. However, given that FCS is a chronic
disease that patients in the APPROACH study had lived with for
many years, study respondentswere likely to accurately recall their
symptoms and life experiences from the period before initiating
volanesorsen. The study design for ReFOCUS did not include
collecting clinical information in the form of TG values, which in
turn does not allow for direct correlation of improvements in QoL
to the corresponding physiologic change. While the data from the
ReFOCUS study complement the clinical findings in the
APPROACH phase III clinical trial, further studies are planned to
show a direct relationship between the effect of volanesorsen on
TG lowering and improvements in patients’ QoL.
5. Conclusions
The ReFOCUS study shows that, following treatment with
volanesorsen, several measures of the QoL of respondents
with FCS improved, including physical, emotional, and cogni-
tive symptoms, and FCS had a reduced impact on personal,
social and professional life. The patient-oriented outcomes
data of this study complement the clinical outcomes reported
from the APPROACH study and suggest that treatment with
volanesorsen has the potential to reduce disease burden and
improve QoL for patients with FCS, whose disease confers a
heavy lifelong clinical and psychosocial burden.
Key issues
● Familial chylomicronemia syndrome (FCS) is a rare meta-
bolic disease caused by the build-up of chylomicrons (chy-
lomicronemia), lipoprotein particles that transport
predominantly dietary fat as well as cholesterol
● The chylomicronemia in FCS brings risks of significant mor-
bidity and mortality, including the threat of acute pancrea-
titis, which can be lethal
● The IN-FOCUS study demonstrated that patients with FCS
experience significant clinical and psychosocial burdens
that reduce their quality of life and limit employment and
social interactions
● Since FCS is a disorder of impaired chylomicron clearance,
treatment has primarily focused on reducing chylomicron
production via restriction of fat intake, that does not guar-
antee sustained reduction of chylomicrons or absence of
risk of acute pancreatitis episodes
● Treatment of FCS patients with the investigational drug
volanesorsen has significantly reduced TG levels in FCS
patients enrolled in clinical trials
● The ReFOCUS study demonstrated that treatment with
volanesorsen had a positive impact on patients’ QoL and
improvement in patients’ activities of daily living across all
domains assessed
● Respondents noted that dietary management of their dis-
ease was easier, and their symptoms more effectively con-
trolled during volanesorsen treatment.
● The survey demonstrated that treatment with volanesorsen
improved the physical, emotional, and neurocognitive
domains associated with FCS
● Improvements lead to a significantly improved overall abil-
ity to perform professional, academic, and social obligations
and improved future outlook on life.
● The research highlights in this patient population a consid-
erable improvement across multiple domains, encouraging
data that underscores the need for a therapeutic option
such as volanesorsen.
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